Login to Your Account

Orexigen Sinks Despite Contrave Efficacy in Phase III Obesity Trial

By Jennifer Boggs

Monday, January 12, 2009

No Abstract


Assistant Managing Editor

Orexigen Therapeutics Inc.'s Contrave hit its endpoints in the first of four Phase III studies, but concerns that the data missed the FDA's benchmark for efficacy in obesity sent shares of the San Diego-based company falling 15.7 percent.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription